We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| HUTCHMED China Limited | AQSE:HCM.GB | Aquis Stock Exchange | Ordinary Share | KYG4672N1198 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.00 | -3.33% | 290.00 | 280.00 | 300.00 | 310.00 | 287.00 | 310.00 | 3,884 | 16:29:52 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMHCM
RNS Number : 9294S
Hutchison China Meditech Limited
29 December 2016
Blocklisting Six Monthly Return
London: Thursday, December 29, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
Hot Features
Premium
1. Name of applicant: Hutchison China MediTech Limited
2. Name of scheme: Hutchison China MediTech Limited Share Option Schemes
3. Period of return: From June 29, 2016 to December 28, 2016
4. Balance under scheme from previous return: 1,417,789 ordinary shares of US$1 each
5. The amount by which the block scheme has been Nil
increased, if the scheme has been increased
since the date of the last return:
6. Number of securities issued/allotted under scheme 56,481 ordinary shares of US$1 each
during period:
7. Balance under scheme not yet issued/allotted at end of 1,361,308 ordinary shares of US$1 each
the period:
8. Number and class of securities originally listed and 2,560,606 ordinary shares of US$1 each admitted on
the date of admission: June 26, 2007
9. Total number of securities in issue at the end of the 60,705,823 ordinary shares of US$1 each
period:
Name of contact: Christian Hogg
Address of contact: 21/F., Hutchison House, 10 Harcourt Road, Hong Kong
Telephone number of contact: +852 2121 8200
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries Christian Hogg, CEO +852 2121 8200 International Media Enquiries Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk Citigate Dewe Rogerson U.S. Based Media Enquiries Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com Investor Relations Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk Citigate Dewe Rogerson Panmure Gordon (UK) Limited Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRUKUBRNAAUURA
(END) Dow Jones Newswires
December 29, 2016 02:40 ET (07:40 GMT)
1 Year HUTCHMED China Chart |
1 Month HUTCHMED China Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
